Clinical trial NCT02879669: A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Official title: A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy
Lead sponsor: Targovax ASA
Sponsor class: INDUSTRY
Collaborators: name: Theradex
First posted: 2016-08-26
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The trial is an open-label, parallel group, multicentre trial that will recruit a total of 30 patients with malignant pleural mesothelioma. The trial will be conducted in 2 phases: a non-randomised safety phase and a randomised phase. The safety phase will consist of a lead-in cohort of 6 patients treated with ONCOS 102 and pemetrexed/cisplatin. The randomised phase will not commence until the DSMB has deemed the safety lead-in data appropriate for continuation. A total of 24 patients will be included in the randomised phase; 14 patients will be randomised to receive ONCOS 102 and pemetrexed/cisplatin, and 10 patients will receive pemetrexed/cisplatin alone. If cisplatin is seen to be too toxic after one or more cycles, the patient may change to carboplatin during the study. Furthermore, if treatment with cisplatin is deemed to be too toxic by the investigator due to age, presence of neurological toxicities or other relevant medical conditions, carboplatin can be administered from start of study. The trial's main objectives are determination of safety, immune activation, clinical response and the correlation between clinical outcome and the immunological data.


Eligibility criteria: Inclusion Criteria:

* Written informed consent.
* Male or female, ≥18 years of age.
* Histologically confirmed unresectable (advanced) malignant pleural mesothelioma in patients who are not candidates for curative surgery and for whom therapy with pemetrexed in combination with cisplatin or carboplatin is considered appropriate. This include:

  * patients who are naïve to chemotherapy,
  * and those who have already received pemetrexed in combination with cisplatin or carboplatin to which their tumour initially responded, but they have relapsed after at least 6 months.

The patient may be evaluated by a multidisciplinary consultation (according to hospital procedure), however the final decision about the inclusion of a patient is made by the principal investigator.

* Measurable disease according to Response Evaluation in Solid Tumour (RECIST 1.1).
* Tumour must be accessible to intratumoural (i.t.) injections and to tumour core needle biopsy or thoracoscopy for tissue sampling and immunohistochemistry analysis.
* The patients must be eligible to receive the study specific chemotherapies, including cyclophosphamide, according to the SPCs and local practice.
* Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance score 0 to 1.
* Acceptable liver, renal, and haematological functions.
* All women of childbearing potential must have a negative urine or serum pregnancy test at screening and all patients must agree to use barrier contraception (i.e. condom) during study treatment and for 2 months after the last virus treatment, 6 months after the last dose of pemetrexed/cisplatin/carboplatin and 12 months after the dose of cyclophosphamide.

Exclusion Criteria:

* Receipt of oncolytic virus treatment, or vaccination with a vaccine containing live virus within 4 weeks before Day 1.
* Use of significant immunosuppressive medication, including high dose corticosteroid (defined as the equivalent of \>10 mg/day prednisone) within 4 weeks before Day 1.
* Patients who participated in a study with an investigational drug or device within 4 weeks prior to Day 1.
* Active bacterial, viral, or fungal infections, requiring systemic therapy.
* Severe arrhythmia, heart failure, previous cardiac infarction, or acute inflammatory heart disease.
* Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient, if included in this study.
* Known infection with HIV, hepatitis B, or hepatitis C.
* Known brain metastases.
* History of organ transplant.
* Females who are pregnant or breast feeding.
* Unwillingness or inability to comply with the study protocol for any reason.
* Patients with pre-existing hearing loss or neuropathy that may worsen due to potential neurotoxicity from cisplatin.
* Patients with a history of hypersensitivity to cisplatin or carboplatin or pemetrexed or cyclophosphamide (or any of its metabolites).
* Patients who are taking phenytoin for prophylactic use.
* History of malignant tumour, unless the patient has been without evidence of disease for at least 3 years, or the tumour was a non-melanoma skin tumour, cervical carcinoma in situ, or prostatic carcinoma in situ.

Primary outcomes:
measure: Number of patients with any (Serious and Non-Serious) Adverse Event measured to assess safety and tolerability
timeFrame: 6 months
Secondary outcomes:
measure: To determine and compare tumour-specific immunological activation in the peripheral blood in the experimental group and the control group. Number of patients in the respective arms with induction of Tumor specific CD8+ T Cells in PBMC
timeFrame: 6 months
measure: To determine and compare immunological activation in tumour mass in the experimental group and the control Group. Number of patients in the respective arms with infiltration of CD8+ T Cells into tumours
timeFrame: 6 months
measure: To determine and compare overall response rate in the experimental group and the control group by number of patients with PD, SD, PR and CR in the respective arms
timeFrame: 6 months
measure: To determine and compare progression-free survival (PFS) in the experimental group and the control group by median time to progression in the respective arms
timeFrame: 6 months
measure: To determine and compare overall survival (OS) in the experimental group and the control group
timeFrame: Until death
measure: To analyse immunological activation by comparing patients with and without presence of tumour antigen recognizing CD8+ T cells
timeFrame: 6 months
measure: To analyse clinical outcome by time to event endpoints (OS and PFS)
timeFrame: 6 months
Other outcomes:
Locations:
city: Dijon
country: France
facility: Centre Georges-François Leclerc
city: Rennes
country: France
facility: CHU de Rennes - Pontchaillou
city: Barcelona
country: Spain
facility: Hospital Universitario Quirón
city: Barcelona
country: Spain
facility: Vall d'Hebron Univerity Hospital
city: Girona
country: Spain
facility: Hospital Universitari de Girona Doctor Josep Trueta - Institut Català d'Oncologia
city: Madrid
country: Spain
facility: Hospital 12 de octubre
city: Madrid
country: Spain
facility: Hospital Universitario HM Sanchinarro
Study officials:
References: